# Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

> **NCT00058071** · PHASE3 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 100 (estimated)

## Conditions studied

- Gestational Trophoblastic Tumor
- Neurotoxicity
- Peripheral Neuropathy
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** amifostine trihydrate

## Key facts

- **NCT ID:** NCT00058071
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058071, "Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00058071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*